Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

785.03 -6.21 (-0.78%)
Official Closing Price Updated: 7:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential. 
Via Benzinga
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company
Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions. 
Via Benzinga
Down 12%, Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Via The Motley Fool
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
1 Profitable Stock with Impressive Fundamentals and 2 to Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
McDonald's Just Got Hammered By Weight-Loss Drugs — Twice
McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned. 
Via Benzinga
Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs
Eli Lilly signed a licensing deal with Juvena for muscle health using its AI-enabled stem-cell protein screening platform. 
Via Benzinga
Hims & Hers Stock Falls After Eli Lilly Rules Out Telehealth Tie-Up: Citi Calls It Aggressive Stance, Retail Turns Bearish
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications. 
Via Stocktwits
Topics Regulatory Compliance
Exposures Legal Regulatory
Should You Buy Eli Lilly Stock Before June 22?
Via The Motley Fool
Topics Economy
Exposures Economy
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
McDonald's Stock Bitten By Big Downgrade Over Weight-Loss Drugs
The fast-food giant was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
2 Weight Loss Drug Stocks That Are Screaming Buys in June
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings. 
Via The Motley Fool
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks. 
Via Benzinga
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36. 
Via Stocktwits
Topics Government
Exposures Political
Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch
The company is planning to soon begin combination studies, testing two of its drugs in weight loss. 
Via Investor's Business Daily
Topics Bankruptcy
Exposures Financial Legal
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
5 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
1 Stock Down 34% This Year to Buy and Hold
Via The Motley Fool
Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years
Via The Motley Fool
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin? 
Via MarketBeat
The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide. 
Via Investor's Business Daily
Novo Nordisk Stock: Is It Still a Smart Buy?
Via The Motley Fool
Time to Buy These 3 Cheap Stocks?
Via The Motley Fool
Should You Invest $1,000 in Eli Lilly today?
Via The Motley Fool
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics
China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma. 
Via Stocktwits
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.